Skip to main content
    G

    Geron Corporation (GERN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.00
    +0.06 (+6.17%)

    Market Cap: $606.81M

    Last updated: Nov 17, 2026 at 4:32 PM ET

    Geron Corporation (GERN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Geron (GERN) has a market cap of $606.81M and an enterprise value of $658.07M. It kept -21.99% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 8.45% above the market cap, as debt exceeds cash.

    Market Cap$606.81M
    Enterprise Value$658.07M
    Latest price (Nov 17, 2026)$1.00

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 100138.11% in the quarter ended Sep 30, 2026 and grew 0.76% a year over 2 years.

    Shares Outstanding672.29M
    Shares Change (YoY)+0.78%
    Shares Change (QoQ)+100138.11%
    Share Count Growth (2Y CAGR)+0.76%

    Valuation Ratios

    Sales and book value multiples are 3.1x and 3.0x. Its year-end P/S ranged from 30.0x to 566.3x from 2016 to 2024.

    P/S Ratio3.1x
    Forward P/S2.6x
    P/B Ratio3.0x

    Valuation history and multiples

    Price Statistics

    The stock is down 10.71% over 52 weeks and trades 13.79% below its 50-day average.

    Beta (1Y)1.42
    52-Week Change-10.71%
    1-Month Change-16.67%
    3-Month Change-37.11%
    6-Month Change-18.03%
    5-Year Change-41.92%
    10-Year Change-51.65%
    Total Return (1Y)-10.71%
    Total Return (3Y CAGR)-20.22%
    Total Return (5Y CAGR)-7.42%
    Return vs SPY (1Y)-21.47%
    Max Drawdown (1Y)-54.13%
    Max Drawdown (3Y)-82.43%
    Sharpe Ratio (1Y)-0.16
    Correlation with SPY (1Y)0.29
    50-Day Average$1.16
    200-Day Average$1.40
    52-Week Range$0.84 to $2.01
    RSI (14 Days)44.7
    Average Volume (20 Days)19.09M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.31x current liabilities, and total debt is 0.53x shareholder equity.

    Current Ratio6.31x
    Quick Ratio4.61x
    Debt / Equity0.53x
    Interest Coverage-1.13x

    Returns and Efficiency

    Return on invested capital is -7.40% over the last 12 months, against a 5-year average of -48.92%.

    Return on Equity (ROE)-21.10%
    Return on Assets (ROA)-9.07%
    Return on Invested Capital (ROIC)-7.40%
    Return on Capital Employed (ROCE)-7.18%
    ROE (5Y Average)-88.55%
    ROA (5Y Average)-43.32%
    ROIC (5Y Average)-48.92%
    Asset Turnover0.40x
    Inventory Turnover0.15x
    Receivables Turnover4.46x
    Cash Conversion Cycle2336 days

    Scores

    GERN has an Altman Z-Score of -2.53, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-2.53
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $217.52M over the last 12 months is up 18.60% from the 12 months before.

    Revenue$217.52M
    Revenue Growth (YoY)+18.60%
    Gross Profit$199.23M
    Operating Income-$32.08M
    Pretax Income-$47.83M
    Net Income-$47.83M
    EBIT-$32.50M
    Reported EPS (TTM)-$0.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 43.01% of the $527.11M in total assets.

    Cash and Equivalents$69.18M
    Total Debt$120.44M
    Net Debt$51.26M
    Net Debt Per Share$0.08
    Working Capital$394.49M
    Shareholder Equity$226.69M
    Book Value Per Share$0.34
    Total Assets$527.11M
    Total Liabilities$300.41M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $661.00K of capital spending, operating cash flow left -$91.19M of free cash flow.

    Operating Cash Flow-$90.53M
    Capital Expenditures$661.00K
    Free Cash Flow-$91.19M
    FCF Per Share-$0.14
    Depreciation and Amortization$2.30M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -14.75%.

    Gross Margin91.59%
    Operating Margin-14.75%
    Pretax Margin-21.99%
    Net Margin-21.99%
    EBIT Margin-14.94%
    FCF Margin-41.92%

    Growth

    Revenue Growth (5Y CAGR)+273.49%
    Book Value Per Share Growth (2Y CAGR)-9.87%
    Tangible Book Per Share Growth (2Y CAGR)-9.87%

    Revenue and profit by year

    Dividends and Yields

    GERN does not pay a dividend. Its free cash flow yield is -13.56%.

    FCF Yield-13.56%
    Buyback Yield-0.72%
    Shareholder Yield-0.72%

    Peer Position

    Against 5 similar companies, GERN has the 4th highest P/S.

    P/S Ratio3.1x vs 4.0x median
    ROIC-7.40% vs -11.69% median
    Revenue Growth (Trailing 4 Quarters, YoY)+18.60% vs -66.55% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 35.59% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+35.59%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GERN

    What is GERN's market cap?

    Geron has a market cap of $606.81M. Its enterprise value, which adds debt and subtracts cash, is $658.07M.

    How many shares of GERN are outstanding?

    Geron has 672.29M shares outstanding. The count is up 0.78% from a year earlier.

    Does GERN pay a dividend?

    No. Geron does not pay a dividend.

    How much debt does GERN have?

    Geron has $120.44M of total debt and $69.18M of cash and equivalents, a net debt position of $51.26M.